Zinc oxide
As of the edition of 20 October 2026, Zinc oxide is a small molecule: marketed, first approved in 1945 (ES).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2006
- Kind
- Small molecule
- Brand name
- Vusion
- First approved
- 1 August 1945 (ES)
- Approvals on record
- 3 in 3 regions
- Holder of the most recent approval
- Viatris; 3 holders in all
- Registered trials
- 5, 0 stopped early
- Disease areas
- Digestive system; Heart and blood vessels; Mouth and teeth; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 2 | 2 | 0 | 0 | 0 |
| Phase 3 | 1 | 1 | 0 | 0 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 5 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Knight Therapeutics | Applicant | 1999 to now |